<DOC>
	<DOCNO>NCT00964795</DOCNO>
	<brief_summary>The primary objective ass long-term safety tolerability Intravitreal Aflibercept Injection ( IAI ; EYLEA速 ; BAY86-5321 ) patient neovascular AMD .</brief_summary>
	<brief_title>Open-label Extension Study Intravitreal Aflibercept Injection ( IAI ; EYLEA速 ; BAY86-5321 ) Neovascular ( `` Wet '' ) Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>The dose evaluate study , Intravitreal Aflibercept Injection ( IAI ; EYLEA速 ; BAY86-5321 ) 2mg , high 2 dose strength evaluate parent study VGFT-OD-0605 ( NCT00509795 ) dose level administer study VGFT-OD-0702 ( NCT00527423 ) , long-term open-label extension study . For reason , dose select extension study . Participants see clinic quarterly visit start day 1 ass safety . Study drug administer as-needed basis discretion investigator minimum allow interval every 4 week maximum allow interval every 12 week . This study assess frequency re-treatment need effect continue Intravitreal Aflibercept Injection ( IAI ; EYLEA速 ; BAY86-5321 ) treatment BCVA .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Participation Study VGFTOD0605 week 96 . In opinion investigator , study eye neovascular AMD may continue require treatment . Presence condition would jeopardize patient 's participation study . Females pregnant , breastfeeding , childbearing potential , unwilling practice adequate contraception throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Eyes</keyword>
	<keyword>Neovascular</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Retina</keyword>
	<keyword>AMD</keyword>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>Best Corrected Visual Acuity</keyword>
</DOC>